Please login to the form below

Not currently logged in

Merck KGaA 'to promote' Stefan Oschmann to chief executive

Germanphamra company reportedly set to elevate him to the top job next year

Merck KGaA Stefan OschmannMerck KGaA is set to elevate its deputy chief executive Stefan Oschmann to replace chief executive Karl-Ludwig Kley, according to local reports.

Manager Magazin says the German pharma company plans to promote Oschmann next year, either after its annual general meeting in May 2016 or when Kley's contract expires in September.

But a Merck spokeswoman told Reuters that a decision on Kley's succession had not yet been made and that this would be a matter for the family-controlled group's board of partners.

Oschmann has been vice chairman of Merck's executive board since January and prior to this was responsible for Merck's Pharma business as Member of the Executive Board from 2011 to 2014.

Before joining Germany's Merck he worked for its namesake Merck & Co as the US company's president of emerging markets for Merck Sharp & Dohme (MSD), as its operations are known outside the US.

Prior to joining MSD Oschmann worked for the International Atomic Energy Agency IAEA from 1985 to 1987 and for the German Animal Health Federation (BfT) from 1987 to 1989.

26th March 2015

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...